McKesson wins new two-year Veterans Affairs contract

Thu Apr 12, 2012 4:30am IST

Related Topics

Stocks

   

(Reuters) - Pharmaceutical wholesaler McKesson Corp on Wednesday said it was selected by the U.S. Department of Veterans Affairs to continue as the VA's prime pharmaceutical supplier for at least two more years.

News of the contract, which includes options for up to three two-year extensions, sent shares of McKesson up more than 4 percent in after hours trading.

The new agreement, valued by the VA at over $31.6 billion, calls for McKesson to supply all of the VA's more than 700 medical centers and outpatient clinics, as well as its seven consolidated mail outpatient pharmacies.

"Over the past eight years, McKesson has partnered with the VA to serve the healthcare needs of America's veterans," Paul Julian, the company's executive vice president and group president, said in a statement.

The VA, which estimated savings of about $3.26 billion through the life of the contract, said the new agreement goes into effect on May 10.

Shares of McKesson, which closed at $87.90 on the New York Stock Exchange, were trading at $91.89 after hours.

(Reporting By Deena Beasley, editing by M.D. Golan)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

HEALTH SHOWCASE

H5N6 Bird Flu

H5N6 Bird Flu

China poultry farm hit in new outbreak of H5N6 bird flu.  Full Article 

Weight Loss

Weight Loss

Low-carb diets may beat low-fat options for weight loss, heart health.  Full Article 

TV and Snacking

TV and Snacking

High-action TV shows lead to more snacking: study.  Full Article 

Fighting Cyberbullies

Fighting Cyberbullies

Family dinners may help kids cope with cyberbullying.  Full Article 

Price Factor

Price Factor

Pricing is key for new heart drugs challenging cheap generics.  Full Article 

Diabetes Care

Diabetes Care

Pistachios may help reduce diabetes risk: study.  Full Article 

'Exciting' Drug

'Exciting' Drug

'Most exciting ever' Novartis drug points to huge sales.  Full Article